Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc.

NASDAQ:HALO

Overview | Financials
Company Name Halozyme Therapeutics, Inc.
Symbol HALO
Currency USD
Price 61.06
Market Cap 7,519,722,180
Dividend Yield 0%
52-week-range 37.73 - 65.53
Industry Biotechnology
Sector Healthcare
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Website https://www.halozyme.com

An error occurred while fetching data.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies

Related Stocks

Acadia Healthcare Company, Inc. logo

Acadia Healthcare Company, Inc.

ACHC

28.17 USD

Nutex Health, Inc. logo

Nutex Health, Inc.

NUTX

45.68 USD

Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

SRPT

98.37 USD

R1 RCM Inc. logo

R1 RCM Inc.

RCM

14.31 USD

ShockWave Medical, Inc. logo

ShockWave Medical, Inc.

SWAV

334.75 USD

Sotera Health Company logo

Sotera Health Company

SHC

11.36 USD

Exelixis, Inc. logo

Exelixis, Inc.

EXEL

36.8 USD

Financials

Numbers are in millions USD

Numbers are in millions USD